Andrew S. Lewis is a venture capital and corporate development executive with a proven history of closing transactions across a variety of deal structures and investment vehicles. He has extensive experience in sourcing, diligence, negotiation, and board-level management in the life science industry. In his current role at the Cystic Fibrosis Foundation he leads end-to-end venture capital investments in companies focused on emerging genetic therapies with curative potential. The CFF invests in excess of $200M/year in cutting-edge science and medical technology. Prior to joining the CFF, he closed 15+ transactions worth over $8B in aggregative total deal value while working at Jazz Pharmaceuticals and Kairos Ventures. At the outset of his career, Andrew also spent several years working as a research scientist in industry-partnered academic laboratories on collaborations with Abbott Laboratories, AstraZeneca, and Bristol Meyer Squibb spanning drug discovery, neuroimaging, and diagnostics.
He holds a Master of Business and Science degree from the Keck Graduate Institute, a Bachelor of Science degree from the University of Illinois in molecular biology, psychology, and philosophy, and a certificate in bioscience intellectual property and patent law from Southwestern U.